Evaluation of human epididymis protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA) as diagnostic tools of type I and type II epithelial ovarian cancer in Japanese women

Tumor Biology

Volumn 36, Issue 2, 2015, Pages 1045-1053

  Fujiwara, Hiroyuki ^a   Suzuki, Mitsuaki ^a   Takeshima, Nobuhiro ^b   Takizawa, Ken ^b   Kimura, Eizo ^c   Nakanishi, Toru ^d   Yamada, Kyosuke ^e   Takano, Hirokuni ^f   Sasaki, Hiroshi ^f   Koyama, Koji ^g   Ochiai, Kazunori ^e  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b CANCER INSTITUTE HOSPITAL   (Japan)

^c Kosei General Hospital   (Japan)

^d AICHI CANCER CENTER HOSPITAL   (Japan)

^e JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g Ueshima Clinic   (Japan)

Author keywords

CA125; Epithelial ovarian cancer; HE4; ROMA; Type I and type II EOC

Indexed keywords

CA 125 ANTIGEN; ESTRADIOL; FOLLITROPIN; HUMAN EPIDIDYMIS PROTEIN 4; MEMBRANE PROTEIN; MUC16 PROTEIN, HUMAN; PROTEIN; TUMOR MARKER; WFDC2 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; DIAGNOSTIC TEST ACCURACY STUDY; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLITROPIN BLOOD LEVEL; HUMAN; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; OVARY CARCINOMA; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK OF OVARIAN MALIGNANCY ALGORITHM; SENSITIVITY AND SPECIFICITY; ALGORITHM; BLOOD; JAPAN; MIDDLE AGED; NEOPLASM; OVARY TUMOR; PATHOLOGY; RECEIVER OPERATING CHARACTERISTIC;

ADULT; AGED; ALGORITHMS; BIOMARKERS, TUMOR; CA-125 ANTIGEN; FEMALE; HUMANS; JAPAN; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROTEINS; ROC CURVE;

EID: 84925506582     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2738-7     Document Type: Article

References (28)

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]: http://globocan.iarc.fr.
2. Valentin L. Use of morphology to characterize and manage common adnexal masses. Best Pract Res Clin Obstet Gynaecol. 2004;18:71–89.
3. Karlan BY. The status of ultrasound and color Doppler imaging for the early detection of ovarian carcinoma. Cancer Invest. 1997;15:265–9.
4. Prat J. New insights into ovarian cancer pathology. Ann Oncol. 2012;23 Suppl 10:x111–117.
5. Kurman RJ, Shih IM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—shifting the paradigm. Hum Pathol. 2011;42:918–31.
6. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609–15.
7. Guth U, Huang DJ, Bauer G, Stieger M, Wight E, Singer G. Metastatic patterns at autopsy in patients with ovarian carcinoma. Cancer. 2007;110:1272–80.
8. Zurawski Jr VR, Knapp RC, Einhorn N, Kenemans P, Mortel R, Ohmi K, et al. An initial analysis of preoperative serum CA 125 levels in patients with early stage ovarian carcinoma. Gynecol Oncol. 1988;30:7–14.
9. Jacobs I, Bast Jr RC. The CA 125 tumor-associated antigen: a review of the literature. Hum Reprod. 1989;4:1–12.
10. Bingle L, Singleton V, Bingle CD. The putative ovarian tumor marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms. Oncogene. 2002;21:2768–73.
11. Galgano MT, Hampton GM, Frierson Jr HF. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol. 2006;19:847–53.
12. Schummer M, Ng WV, Bumgarner RE, Nelson PS, Schummer B, Bednarski DW, et al. Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene. 1999;238:375–8.
13. Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2008;108:402–8.
14. Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2009;112:40–6.
15. Kim YM, Whang DH, Park J, Kim SH, Lee SW, Park HA, et al. Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer: a prospective case–control study in a Korean population. Clin Chem LabMed. 2011;49:527–43.
16. Ruggeri G, Bandiera E, Zanotti L, Belloli S, Ravaggi A, Romani C, et al. HE4 and epithelial ovarian cancer: comparison and clinical evaluation of two immunoassays and a combination algorithm. Clin Chim Acta. 2011;412:1447–53.
17. Moore RG, Miller MC, Disilvestro P, Landrum LM, Gajewski W, Ball JJ, et al. Evaluation of the diagnostic accuracy of the Risk of Ovarian Malignancy Algorithm in women with a pelvic mass. Obstet Gynecol. 2011;118:280–8.
18. Bandiera E, Romani C, Specchia C, Zanotti L, Galli C, Ruggeri G, et al. Serum human epididymis protein 4 and Risk for Ovarian Malignancy Algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management. Cancer Epidemiol Biomarkers Prev. 2011;20:2496–506.
19. Yemelyanova AV, Cosin JA, Bidus MA, Boice CR, Seidman JD. Pathology of stage I versus stage III ovarian carcinoma with implications for pathogenesis and screening. Int J Gynecol Cancer. 2008;18:465–9.
20. Lu D, Kuhn E, Bristow RE, Giuntoli II RL, Kjaer SK, Shih IM, et al. Comparison of candidate serologic markers for type I and type II ovarian cancer. Gynecol Oncol. 2011;122:560–6.
21. Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brunner N, Chan DW, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in testicular, prostate, colorectal, breast and ovarian cancer. Clin Chem. 2008;54:e11–79.
22. Molina R, Filella X, Bruix J, Mengual P, Bosch J, Calvet X, et al. Cancer antigen 125 in serum and ascitic fluid for patients with liver disease. Clin Chem. 1991;37:1379–83.
23. Park Y, Lee JH, Hong DJ, Lee EY, Kim HS. Diagnostic performances of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases. Clinical Biochem. 2011;44:884–8.
24. Nolen B, Velikokhatnaya L, Marrangoni A, Geest KD, Lomakin A, Bast Jr RC, et al. Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol Oncol. 2010;117:440–5.
25. Moore RG, Jabre-Raughley M, Brown AK, Robison KM, Miller C, Allard WJ, et al. Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol. 2010;203:228.e1-6
26. Chan KK, Chen CA, Nam JH, Ochiai K, Wilailak S, Choon AT, et al. The use of HE4 in the prediction of ovarian cancer in Asian women with a pelvic mass. Gynecol Oncol. 2013;128:239–44.
27. Sandri MT, Bottari F, Franchi D, Boveri S, Candiani M, Ronzoni S, et al. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome. Gynecol Oncol. 2013;128:233–8.
28. Kristjansdottir B, Levan K, Partheen K, Sundfeldt K. Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer. Gynecol Oncol. 2013;131:52–8.